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Stlmmary 
During feeding, infected mosquitos inject malaria sporozoites into the host circulation. Within 
minutes, the parasites are found in the liver where they initiate the first stage of malaria infection. 
All species of malaria sporozoites are uniformly covered by the circumsporozoite protein (CS), 
which contains a conserved COOH-terminal sequence called region II-plus. We have previously 
shown that region II-plus is the parasite's  hepatocyte-binding ligand and that this ligand binds 
to heparan sulfate proteoglycans (HSPGs) on the hepatocyte membrane. Using a series of substituted 
region II-plus peptides, we show here that the downstream basic amino acids  as well as the 
interdispersed hydrophobic residues are required for binding of CS to hepatocyte HSPGs.  We 
also show that this positively charged stretch of amino acids must be aggregated in order to 
bind to the receptor. On the basis of this information, we have synthesized a multiple antigen 
peptide that mimics the hepatocyte-binding ligand. This construct inhibits both CS binding 
to HepG2  cells in vitro as well as CS clearance in mice. 
M 
alaria is transmitted when Anopheles mosquitos inject 
sporozoites into susceptible vertebrate hosts. Within 
minutes after injection, the sporozoites are cleared from the 
bloodstream and found in the liver, where they cross the space 
of Disse and invade hepatocytes. The rapidity of invasion and 
the uniqueness of the cellular target strongly suggest that 
the parasite is arrested in the liver by specific receptors. Sev- 
eral lines of evidence indicate that the initial event is the rec- 
ognition of the parasite's coat protein (drcumsporozoite protein 
[CS] 1)  by  heparan  sulfate  proteoglycans  (HSPGs)  on  the 
membrane of hepatocytes (1, 2). The ligand is contained in 
the COOH-terminal  of CS,  in a region highly conserved 
among all species of mammalian malaria parasites.  Here we 
designate the conserved motif as region II-plus because it en- 
compasses part of the previously defined region II (3), as well 
as a stretch of positively charged amino acids at the 3' end 
(see Fig.  1). 
A similar motif is found in several host proteins, such as 
thrombospondin,  the complement proteins properdin and 
complement protein 6 (C6) (4-6), F-spondin (7), UNC-5, 
a molecule that guides pioneering axon migration in Caenor- 
habditus elegans (8), thrombospondin-related anonymous pro- 
tein (TRAP) or sporozoite surface protein 2 (SSP-2), another 
1Abbreviations used in  this paper: C6,  complement protein 6;  CS, 
circumsporozoite protein; HSPG, heparan sulfate proteoglycan; MAP, 
multiple antigen peptide; SSP-2, sporozoite  surface  protein 2; TBS, Tris- 
buffered saline; TRAP, thrombospondin-related  anonymous  protein. 
malaria surface protein (4, 9, 10), and EtHL6, a protein from 
the coccidian parasite Eimeria tenella (11) (see Fig. 1). Although 
the function of the motif in this diverse group of proteins 
is unknown, synthetic peptides representing the motif, or 
subregions of the motif, are biologically active in vitro and 
in vivo. Some of these peptides inhibit platelet aggregation 
and melanoma cell metastasis (12), whereas others have an- 
tiangiogenic activity (13) and display cell-adhesive properties 
(14-16).  In view of the postulated importance of the motif 
in the initial phases of malaria infection as well as in a variety 
of cellular interactions in the mammalian host, we have de- 
termined some of the structural features of region-II plus re- 
quired for activity in a malaria model, i.e.,  for adhesion of 
CS to hepatocytes in vitro and its clearance by hepatocytes 
in vivo. 
Materials and Methods 
Recombinant Proteins.  The Escherichia coli-derived recombinant 
CS27IVC  (27-123[NANPNVDP]3[NANP]21300-411) represents 
the complete Plasmodiumfakiparum CS sequence from the T4 iso- 
late,  except that  the hydrophobic NH2- and  COOH-terminal 
amino acids 1-26 and 412-424 have been deleted and five histidine 
residues have been added to the COOH-terminus to facilitate 
purification (17). The recombinant protein used in these studies 
was kindly provided by Dr. Bela Takacs (F. Hoffmann-La Roche 
Ltd.,  Basel, Switzerland). 
Antibodies.  The mAb 2A10 (18) is directed against an epitope 
contained in the (NANP)n repeat domain of P. fakiparum CS. The 
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ghei CS. The mAb 2E6, a gift from Dr. M. Tsuji (New York, Univer- 
sity Medical Center) reacts with the liver stage of P.  berghei. 
Peptides.  Peptides were synthesized by Boc chemistry, using the 
multiple peptide synthesis method described by Houghten  (20). 
Cleavage from the resin was performed with low-high hydrofluoric 
acid.  Purity was verified  by HPLC and amino acid  analysis,  and 
in some cases,  by mass spectrometry. Multiple antigen peptides 
(MAPs) were made as described by Tam et al. (21). Each MAP con- 
tains four copies of its respective peptide linked to a core of three 
lysines prepared from branching two levels of Boc-Lys (Boc)  and 
using y-butyric acid and ~-alanine as spacers. The cysteines in the 
region II-plus MAPs were blocked with acetamide groups. Three 
MAPs were synthesized utilizing the following peptides: QCN- 
VTCGSGIRVRKRKGSN (P. berghei region II-plus), PCSVTC- 
GNGIQVRIKPGSA (P.fakiparum region II-plus), and NANPNA- 
NPNANPNANP  (P. falcipamm  repeat). Peptide CSVTCG was a 
gift from Dr. George Tuszynski (Medical College of Pennsylvania, 
Philadelphia,  PA).  Cysteine-containing peptides, with the excep- 
tion of the MAPs, contained free sulfhydryl groups as detected by 
the Ellman reaction (22), but were Ellman negative after oxidation 
by long-term storage at  -20~  or by stirring in 10 mM Tris, pH 
8,  overnight,  at concentrations from 1 to  10 mg/ml. 
Mice.  BALB/C females from Taconic Farms Inc. (Germantown, 
NY) weighing between  15 and 20 g  were used. 
Binding of CS to HepG2 Cells.  HepG2 cells,  a hepatoma cell 
line,  (ATCC HB8065; American Type Culture Collection, Rock- 
ville, MD) were maintained in MEM (GIBCO BRL, Gaithersburg, 
MD), 10% FCS (Hyclone Laboratories, Logan, UT), I mM gluta- 
mine (GIBCO BRL), 3 mg/ml glucose (Sigma Chemical Co., St. 
Louis, MO), and lx  nonessential amino acids (GIBCO BRL) (FCS- 
MEM). Cells (10  s) were deposited in 96-well plates (RemovaweU 
tissue culture plates; Dynatech Laboratories, Inc., Chantilly, VA), 
allowed  to  grow  overnight,  fixed  with  4%  paraformaldehyde 
(Eastman Kodak Co., Rochester, NY) for 10 rain, rinsed three times 
with Tris-buffered saline  (TBS;  130 mM NaC1,  50 mM Tris, pH 
7.4), and then blocked for 2 h at 37~  with 1% BSA in 130 mM 
NaC1,  50  mM  Tris-HC1,  and  0.02%  sodium  azide,  pH  7.4 
(TBS/BSA). The cells were incubated with various concentrations 
of peptide in TBS/BSA for 1 h at 37~  washed three times with 
TBS, incubated with recombinant CS at 2-5 #g/ml in TBS/BSA 
for I h at 37~  washed three times with TBS, and finally incubated 
with  mI-labeled mAb  2A10  (2  x  10  s  cpm/well)  for 30  rain, 
washed three times with TBS, and then counted in a LKB 3~-counter 
(model 1260; Pharmacia,  Inc., Piscataway, NJ). The inhibitory ability 
of peptide fractions obtained after gel filtration chromatography 
was tested either in column buffer (TBS, pH 6.45),  or in TBS, 
pH 7.45,  with identical results. 
Molecular Sieving Chromatography.  To separate peptide monomers 
from aggregates, peptides were filtered through columns containing 
Sephadex superfine G-50 (Pharmacia, Inc.) equilibrated in TBS, pH 
6.45, except as noted in the text. Peptides containing 20 or more 
amino acids were dissolved in 200 ~1 of column buffer, loaded onto 
a 30-ml column (C16/20, Pharmacia), and eluted with a flow rate 
of 5 cm/h. 0.8-ml fractions were collected and peptide concentra- 
tion was measured in a spectrophotometer by absorbance at 220 
nm. Separation of aggregates from monomers of smaller peptides 
(15 amino acids) was performed in a C16/70 column (Pharmacia) 
with a bed volume of 120 ml. 
Mass Spectrometry.  Mass spectra of different fractions of the re- 
gion II-plus peptide were measured using a time-of-flight mass spec- 
trometer constructed at the Rockefeller University (23,  24).  1 #1 
of 20  #M  of each  fraction  in  water  was  mixed  with  9  #1  of 
c~-cyano-4-hydroxycinnamic acid (10 g/liter in formic acid/water/iso- 
propanol [1:3:2, vol/vol/vol]), and 0.5 #1 of this solution was placed 
on the mass spectrometer probe tip and dried with a stream of 
cold air. The sample was irradiated with 10-ns laser pulses (wave- 
length 355 nm) from a Nd (YAG) laser. The ions created were ac- 
celerated in an electrostatic field and their time-of-flight was mea- 
sured with a transient digitizer (model 8828D; LeCroy Research 
Systems, Corp., Spring Valley, NY). To improve the statistics,  200 
individual spectra were added together. The time-of-flight spectra 
were converted into mass spectra using dynorphin 1-17 as an in- 
ternal calibrant. 
Reduction and Alkylation of P. berghd Sporozoites.  10  s sporozoites 
were resuspended in 4.8 M urea, 1 mM EDTA, 50 mM dithiothre- 
itol (DTT; Sigma Chemical Co.), and incubated at 25~  for I h. 
N-ethylmalemide (Sigma Chemical Co.) was then added to a final 
concentration of 100 mM, and incubation proceeded for 30 min 
at 25~ 
SDS-PAGE and Western Blotting.  SDS-PAGE was performed in 
7.5%  slab  gels.  Approximately 104 sporozoites were loaded per 
lane in either reducing or nonreducing conditions.  For Western 
blotting,  the gel contents were electrophoretically transferred to 
an Immobilon membrane (Millipore Corp., Bedford, MA).  The 
membrane was blocked for 1 h with TBS/BSA, incubated for I h 
with 5 #g/ml ofmAb 3Dll in TBS/BSA, washed three times with 
TBS/0.05% Tween, and incubated with rabbit anti-mouse Ig cou- 
pled to alkaline-phosphatase (Sigma Chemical Co.) for 1 h. The 
membrane was then washed three times with TBS/0.05% Tween, 
and the bound enzyme was revealed with bromochlorophenol blue 
and nitrotetrazolium blue (both from Sigma Chemical Co.) in 100 
mM Tris-HC1,  100 mM NaC1,  5 mM MgCI2, pH 9.0. 
Assay for Sporozoite Infectivity.  This was performed according 
to the methods described by Hollingdale et al.  (25)  and Sinden 
et al. (26). HepG2 cells were plated in FCS-MEM at a density of 
10  s cells/ml in eight-chamber slides (model 4808; Lab-tek, Naper- 
ville, IL) 48 h before each experiment. P. berghei sporozoites were 
dissected  from mosquito salivary glands and resuspended in TBS, 
pH 7.45,  containing either P.  berghei region II-plus peptide ag- 
gregates, monomers, or buffer alone.  In the experiment with the 
MAPs, the parasites  were resuspended in FCS-MEM alone,  with 
the repeat region MAPS, or with P. berghei region II-plus MAPs. 
Sporozoites (10  s) were then added to each well and the parasites 
were incubated with the HepG2 cells for 2 h at 37~  The medium 
was removed after 2 h and replenished with fresh FCS-MEM. The 
medium was changed again at 18 and 28 h, and after 48 h the cul- 
tures  were  fixed  with  cold  methanol  containing  0.3%  HzO2. 
Wells  were blocked with TBS/BSA (without  azide) for 45  rain 
at 37~  incubated for 45 rain at 37~  with 10/~g/ml mAb 2E6, 
washed six times with TBS/0.05%  Tween, incubated for 45 min 
at 37~  with goat anti-mouse Ig conjugated to horseradish per- 
oxidase (Accurate Chemical & Scientific  Corp., Westbury, NY), 
and washed six times with TBS/0.05%  Tween.  The bound en- 
zyme was revealed with 1 mg/ml 3,Y-diaminobenzidine  (Sigma 
Chemical Co.) in 0.05 M  Tris, pH 7.6, 0.1% H202. Slides were 
mounted in 50% glycerol in PBS and the number of exoerythro- 
cytic forms in each well was counted under a  x20 objective. 
Radiolabeling of Proteins.  The mAb 2A10 was labeled with 12sI 
(Amersham,  Arlington  Heights,  IL) to  asp  act  of "~3  x  106 
cpm/#g using iodogen (Pierce,  Rockford, IL), according to the 
manufacturer's instructions.  Recombinant CS used for in vivo studies 
was labeled to a lower specific activity (',~2.5  x  105 cpm/#g) with 
a milder procedure in order to reduce oxidative damage to the pro- 
tein.  1 mCi of 12sI was oxidized in 25 #1 of 0.1 M  sodium phos- 
phate buffer, pH 7.4,  for 5 min in a glass tube precoated with io- 
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Figure  1.  Schematic  representation of the CS with region II-plus se- 
quences and homologous sequences from other  proteins. (REPEATS) 
Species-specific  tandem repeats of amino acids. Region I (R/) A conserved 
group of amino acids, KLKQP, NH2-terminal to the repeats. Region II- 
plus (R-II *) A conserved group of amino acids COOH-terminal  to the 
repeats (3). Below are region II-plus sequences from a variety of malaria 
parasites. (Boxes) Highlight different portions of this motif: an upstream 
tryptophan residue, a cysteine-containing  region, and a downstream  "plus" 
region containing basic and hydrophobic  residues. Also shown are homol- 
ogous sequences from thrombospondin, properdin, the C. elegans protein 
UNC-5, complement protein 6 (C6),  the neuronal adhesion molecule 
F-spondin, another malaria surface protein TRAP, and the E. tenella pro- 
tein EtHL6. The amino acid sequences derive from the following sources: 
P.falcitmrum (42); P. vivax (43), P. malariae  (44); P. knowlesi (45); P. cynomolgi 
(46); P. brasilianura (47); P. berghei (48); P. yoelii (49); thrombospondin (4); 
complement proteins properdin and C6 (5, 6); UNC-5 (8); F-spondin (7); 
TRAP (4); and EtHL6 (11). 
dogen. This  solution was then transferred  to another tube and 
incubated for 5 min on ice with 20/,1 of CS27IVC (1.28 mg/ml). 
The free iodide was removed by filtration  in Sephadex G-25 (Isolab, 
Inc., Akron, OH). The labeled CS was then subjected to chroma- 
tography in a heparin-Sepharose column (Sigma  Chemical Co.) 
in order to separate CS aggregates (active fraction) from monomers 
(inactive fraction). For this purpose, the heparin-Sepharose was equi- 
librated with TBS/BSA (without azide), the iodinated protein was 
added,  and the column was washed with five-column volumes of 
buffer. The bound, aggregated CS was eluted with I ml of 50 mM 
Tris,  1.5 M  NaC1,  pH 7.4,  and stored at 4~  until use.  Under 
these conditions, the labeled aggregates maintained their heparan- 
binding activity for about 3 d  and decayed gradually thereafter. 
Clearance Studies.  Mice were anesthetized with ether and in- 
jected with 500/zg of peptide in PBS, or with PBS alone via the 
periorbital sinus.  5 min after injection, they were injected  via the 
opposite periorbital  sinus with 10  s cpm of radiolabeled CS in PBS. 
The mice were killed  2 min after  this  last  injection.  They were 
exsanguinated and their organs were removed, rinsed in TBS, blotted 
dry, weighed,  and counted in an LKB y-counter. 
Results 
In a previous publication  (1),  we reported  that  a region 
II-plus peptide,  containing a COOH-terminal extension of 
B 
PCSVTCGNGIQVRIKPGSAN  (Ia) 
PCSVTCGNGIQVRIKPaAN  (Ib) 
PCSVTCGNGIQVRIK  (II) 
PCSVTCGNGIQVEIEPGSAN  (III) 
PCSVTCGNGIQVEIKPGaAN  (IV) 
PCaVTCGNGIOVNIN  (V) 
PCaVTCGNGaQSRIK  (VI) 
CaVTCG  (VII) 
GNGIQVRIKPGSAN  (VIII) 
CGNGIQVRIKPGSAN  (IX) 
QCNVTCGaGIRVRKRKGaNKKAEDL  (X) 
P.  berghet  region  II  plus 
OCNVTCGSGIRVRKRKGSN'-..~ 
QCNVTCGSGI  RVRKRKGSN~'~  K 
P.  faZclparua  region  II plus 
pCSVTCGNG  IQVRI  KPGSA  ~  K 
PCSVTCGNGIQVRIKPGSA~ 
PCSVTCGNGIQVRIKPGSA~ K,  / 
PCSVTCGNG  IQVR  I KPGSA/ 
P.  falctparum  repeat  region 
NANPNANPNANPNANP 
NANPNANPNANPNANP  K~,,~ 
Figure  2.  Linear  and multiple antigen peptides (MAPs). (A) Peptide 
Ia was used in our original studies (1) and represents the P. fakiparum re- 
gion II-plus with a five  amino acid  extension at the COOH-terminal end. 
Peptides Ib-IX are truncated and modified  versions of this peptide (asterisks 
indicate the changed residues). Peptide X is P. berghei region II-plus used 
in the sporozoite  invasion assays. (B) A schematic  representation of MAPs 
made from P. berghei  and P.falciparum region II-plus and from P.fakiparum 
central repeats. 
299  Sinnis  et al. five amino acids (peptide Ia, Fig.  2), inhibited  the binding 
of recombinant P. fakiparum  CS to HepG2 cells.  Here we 
used a series of substituted and truncated peptides (peptides 
Ib-IX, Fig. 2) to study the structural requirements  for the 
ir~teraction  of region II-plus with hepatocytes. As shown in 
Fig. 3, removal of the COOH-terminal  glycine (peptide Ib, 
Fig. 2) or of the five COOH-terminal  amino acids from the 
original  peptide (peptide II,  Fig.  2),  have no effect on the 
inhibitory  activity of the peptide.  We also made substitu- 
tions in the cluster of positively charged amino acids at the 
COOH-terminal end of the motif. A peptide in which only 
the arginine is replaced with glutamic acid (peptide IV, Fig. 
2) is less active than the original peptide. When both lysine 
and arginine are replaced by either glutamic acid or asparagine 
(peptides III and V,  Fig.  2),  the peptides are inactive (Fig. 
3). Adjoining the positively charged amino adds, all CS have 
two to three hydrophobic residues (Fig.  1), e.g., isoleucine 
and valine in P.falciparum.  If these are replaced by serine (pep- 
tide VI, Fig. 2), most inhibitory activity is lost (Fig. 3). De- 
spite the importance of the downstream basic/hydrophobic 
residues, when this portion of region II-plus (peptide VIII, 
Fig. 2) is separated from the cysteine-containing portion of 
the motif (peptide VII,  Fig.  2), neither peptide has inhibi- 
tory activity (Fig.  3). 
Previously it has been shown that if the two cysteines are 
replaced by alanines or chemically modified to prevent disulfide 
bond formation, the region II-plus peptide loses activity (1). 
lOO 
~ercent inhibition 
6o  /~ 
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Figure 3.  Peptide  inhibition of CS binding to HepG2 cells. Paraform- 
aldehyde-fixed  HepG2  cells  were preincubated  with peptides at concentra- 
tions between 0 and 125/zg/ml, washed, and incubated with CS27IVC 
at 2.5 to 5/zg/ml.  After washing, cells were incubated with iodinated 
mAb 2AlO, washed, and bound antibody was counted in a 3'-counter. 
Shown is percent inhibition of binding of CS271VC to HepG2 cells in 
the presence of peptide compared with results obtained in the absence of 
peptide. Each peptide concentration was assayed  in triplicate, and standard 
deviations were not greater than 5%. Changed amino acids are under- 
lined: (~-) PCSVTCGNGIQVRIKPSAN;  ( ￿9 ) PCSVTCGNGIQVRIK; 
(&)  PCSVTCGNGIQVEIKPGSAN;  (~(-)  PCSVTCGNGSQS  _- 
RIK; (A) GNGIQVRIKPGSAN; ([]) CSVTCTGNGIQVEI_EPGSAN; 
(O) PCSVTCGNGIQVNIN; (+) CSVTCG; and (V) CGNGIQVtLI- 
KPGSAN. 
To examine the possibility that inhibitory activity is associated 
with disulfide-linked aggregates,  the region II-plus peptide 
(peptide Ib, Fig. 2) was subjected to molecular sieving chro- 
matography through  Sephadex G-50.  The profile obtained 
is complex, indicating the presence of molecules of various 
sizes (Fig. 4). The Sephadex fractions also differ in their con- 
tents of free sulfhydryl groups as detected by the Ellman reac- 
tion. Fractions 24-30 from the low molecular weight peak 
are Ellman positive, whereas the fractions  14-23 from the 
first peak and from the preceding shoulder are negative.  Anal- 
],sis of the Sephadex fractions by mass spectrometry is shown 
in Fig. 5. Fraction 25 from the low molecular weight peak 
contains monomers almost exclusively (Fig.  5 A).  Fraction 
22 from the high molecular weight peak contains dimers and 
probably noncovalently associated monomers (Fig. 5 B). Frac- 
tion 17 from the shoulder is a mixed aggregate ofcovalently 
bound tetramers, trimers, and probably dimers and noncova- 
lently associated monomers (Fig.  5 C). Because monomers 
and double-charged dimers have similar profJes by mass spec- 
trometry (Fig. 5, B and C) we cannot determine the propor- 
tion of noncovalently associated monomers in the dimer and 
aggregate  fractions  (frx 22 and  17). 
The various fractions were then assayed for activity. As 
shown in Fig. 4, only those fractions containing dimers and 
higher molecular weight aggregates inhibit binding of CS 
to HepG2 cells.  The monomeric species  is totally inactive. 
To examine the possibility that  the lack of activity in  the 
monomers is due to the presence of free sulfhydryls, we air- 
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Figure 4.  Size  fractionation of region II-plus peptide with binding ac- 
tivity of different fractions. Crude region II-plus peptide (peptide lb, Fig. 
2) was run over a G-50 sizing column equilibrated in TBS. (Solid line) 
Absorbance at 220 nm of the fractions. Fractions 14-23 are Ellman nega- 
tive and fractions 24-30 are Ellman positive. Each fraction was then tested 
for inhibition of binding of CS to HepG2 cells. Paraformaldehyde-fixed 
cells were incubated with the column fractions for 1 h, washed, and then 
incubated with CS27IVC at 2.5 #g/ml for 1 h, followed  by iodinated mAb 
2A10. (Dotted line) Percent inhibition of binding of CS to HepG2 cells. 
Each point was assayed  in triplicate and standard deviations were within 
5% of the mean. As shown, only the muhimer containing fractions have 
inhibitory activity. 
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Figure  5.  Mass spectrometry  of region II-plus peptide fractions 17, 22, 
and 25. [mM+nHl"§ designates the clusters of the intact molecule (m =1, 
monomer; m =2, dimer;  m =3, trimer; tn =4, tetramer)  with n protons 
attached to it. (.4) The spectrum from fraction 25. (/3) The spectrum from 
fraction  22.  (C) The spectrum  from fraction  17. As indicated,  the first 
peak in B and C contains  monomers and double-charged  dimers which 
oxidized the crude peptide at pH 8.0 before subjecting it to 
size exclusion chromatography. The profile obtained was iden- 
tical to the one shown in Fig. 4, except that none of the frac- 
tions were EUman positive. The oxidized monomers from 
this  experiment  also  lacked  inhibitory  activity  (data  not 
shown). 
We have also analyzed the composition of two inactive 
peptides with modified COOH-terminal  regions (peptides 
III and VI, Fig. 2).  It could be argued that these peptides 
are not able to inhibit binding of CS to HepG2 cells (Fig. 
3)  because  the  substitutions  rendered  them  incapable  of 
forming aggregates rather than incapable of binding to HPSGs. 
As shown in Fig. 6, the chromatographic profiles of oxidized 
peptides  PCSVTCGNGSQSRIK  and  PCSVTCGNGIQV- 
EIEPGSAN  are indistinguishable  from the profile of the- 
native region II-plus peptide (Fig. 3). Nevertheless, the frac- 
tions containing aggregates of the modified peptides had no 
inhibitory activity (data not shown). 
In other experiments, we tested a peptide containing a single 
cysteine, CGNGIQVRIKPGSAN. This peptide can only form 
disulfide-linked dimers upon oxidation, and it is inactive (Fig. 
3). In a previous publication (1) a longer peptide containing 
a single cysteine CGNGIQVRIKPGSANKPKDE  had some 
inhibitory activity.  The reason for this discrepancy is not 
known. However, the extra basic residues at the COOH ter- 
minus may increase the binding avidity of these longer dimers 
for the HSPGs  of HepG2 cells. 
Taken together, these experiments indicate that one of the 
functions of the region II-plus cysteines may be to assemble 
muhimers of the downstream basic amino acids, thereby in- 
creasing the binding activity of CS for the negatively charged 
HSPG receptors on the hepatocyte surface. To obtain further 
support for this hypothesis, we synthesized region II-plus 
peptides in which the cysteines were blocked with acetamide 
groups and assembled them as the four arms of a MAP (Fig. 
cannot be distinguished  from one another by m/z. This is also the case 
for the dimer peak in C which may include  double-charged  tetramers. 
The exponential background,  most evident in C, is due to fragmentation 
and/or clustering  of matrix ions. 
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Figure 6.  Size fractionation  of 
region II-plus peptides with down- 
stream substitutions.  (,4) 0.5 mg of 
peptide  PCSVTCGNGIQVEIE 
PGSAN, with the changed residues 
underlined,  was loaded onto a 30- 
ml Sephadex G-50 column and run 
with a linear flow rate of 5 cm/h. 
(B) 0.5  mg of peptide  PCSVTC- 
GNGSO~RIK, with the changed 
residues underlined, was loaded onto 
a  60-ml  Sephadex  G-50  column 
and run with a linear flow rate of 
5 cm/h. A larger column was neces- 
sary for adequate separation of the 
aggregates  from the monomers of 
this  smaller  peptide.  As  shown, 
these profiles are virtually identical 
to that of the original peptide shown 
in Fig.  3. 
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Figure  7.  Region ll-plus MAPs inhibition of CS protein binding to 
HepG2 cells. Paraformaldehyde-fixed HepG2 cells were incubated with 
the indicated concentrations of MAPs for 1 h, washed, and then incubated 
with 5/~g/ml of CS, followed by iodinated mAb 2A10. Shown is percent 
inhibition  of binding  of CS to HepG2 cells in the presence of MAPs com- 
pared with CS binding in the absence of MAPs. Each point represents 
the mean of triplicate samples. (+) P. berghei region II-plus MAPS; (.-~-) 
P.fakiparum region lI-plus MAPs; and ( ￿9 ) P.fakiparum repeat-region  MAPs. 
Figure 8.  Western blot of native CS. 
(Lane I) 104 freshly isolated sporozoites 
were reduced for I h in 4.8 M urea, 1 mM 
EDTA, 50 mM DTT, alkylated with 100 
mM  N-ethylmalemide,  and  then 
resuspended in sample buffer with 5% 
3-ME.  (Lane 2)  An equal  number of 
freshly  isolated  sporozoites  were 
resuspended  in  nonreducing  sample 
buffer. Both samples were subjected to 
SDS-PAGE, followed  by Western blotting 
revealed  with mAb 3Dll. As shown, the 
native CS contains large aggregates as well 
as monomeric forms. These aggregates 
are no longer present after the parasites 
are reduced and alkylated. The two bands 
in the reduced and alkylated extract cor- 
respond to the membrane form of CS and 
the presumed intracellular precursor (27). 
2). As shown in Fig. 7, MAPs with peptide arms representing 
region II-plus ofP.  berghei  and P. fakiparum inhibit binding 
of CS to HepG2 cells in a dose-dependent manner, whereas 
control MAPs  with  (NANP)4  arms  are inactive. 
Having established that region II-plus peptide aggregation 
is required for binding to HepG2 cells, we examined the struc- 
ture of native CS from P. berghei. Sporozoites were isolated 
from salivary glands of mosquitos, suspended in sample buffer, 
and immediately subjected to SDS-PAGE under nonreducing 
conditions.  A  Western blot  of this gel  (Fig.  8)  shows the 
Figure 9.  Peptide aggregates and region II-plus MAPs inhibit  P. berghei sporozoite invasion of HepG2 cells. (.4) A typical fractionation of the P. berghei 
region II-plus peptide using TBS, 7.4, as the column buffer. Fractions 17 (aggregates) and 22 (monomers) were then used in the HepG2 invasion assay 
with sporozoites. (B) Results from three invasion assays using P. berghei region II-plus fractions. In Exp. 4 the P. berghei region II-plus MAPs is used 
with the repeat region MAPs as a control.  HepG2 cells were plated at a density of 5  x  10S/ml, and incubated for 2 h with P. berghei sporozoites 
in the presence of peptide  aggregates or monomers.  Cells were grown for 2 d,  fixed, and stained with mAb 2E6, followed by goat  anti-mouse Ig 
conjugated to horseradish peroxidase, The exoerythrocytic forms of the parasite in each well were then counted under a  x20 objective. Three samples 
of each peptide fraction were assayed in each experiment. Percent inhibition  was calculated with reference to controls in which sporozoites were allowed 
to invade in the presence of column buffer or medium alone. 
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cellular precursor  (27) as well as aggregates of both mole- 
cules. After reduction and alkylation,  the higher molecular 
weight aggregates are no longer present  (Fig. 8). 
Next, using a Sephadex G-50 column, we separated high 
and low molecular weight fractions from oxidized P. berghei 
region II-plus (peptide X, Fig. 2) and assayed them for the 
ability to inhibit sporozoite invasion of HepG2 cells. At the 
concentrations  tested, only the high molecular weight frac- 
tions inhibited sporozoite invasion (Fig. 9). We also tested 
the inhibitory activity of the P. berghei region II-plus MAPs 
on sporozoite invasion in vitro and as shown in Fig. 9, they 
are also active. 
We have previously shown that recombinant CS aggregates 
(but not monomers) are rapidly cleared from the bloodstream 
of mice and accumulate on hepatocytes (28). To examine the 
effect of MAPs on CS clearance, mice were injected intrave- 
nously with 500/~g of thee P. berghei region II-plus MAPs 
and 5 min later  with t25I-labeled CS aggregates.  Control 
mice were injected  with  (NANP)4  MAPs  or with buffer 
alone, followed by a second injection with the CS aggregates. 
All mice were killed 2 min after CS injection, and their blood 
and organs were harvested and counted in a "y-counter. As 
seen in Fig. 10, the P. berghei region II-plus MAPs inhibited 
about 50% of the CS protein homing to the liver. Most of 
the CS that had not been cleared by the liver was still cir- 
culating in the blood. In other experiments, the same proce- 
dure was repeated except that the mice were killed after 15 
rain. At this time, there was no signficant difference  between 
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Figure 1O.  Peptide inhibition of CS homing to the liver. Mice were 
injected with either 0.5 mg of MAPs in PBS or with the same volume 
of PBS alone.  5 min later they were injected  with 100,000 cpm of CS 
protein, and then killed 2 rain after this  second injection.  At this time 
the mice were exsanguinated,  their organs  were harvested and washed, 
and radioactivity  in each organ and in the blood was measured.  Shown 
is the percent  injected  counts per minute found in the liver and blood 
of nine mice. Three mice preinjected  with PBS alone (slanted line bars), 
three mice preinjected  with repeat-region  MAPs (dotted  bars),  and three 
mice preinjected  with region lI-plus MAPs (solid bars). The mice prein- 
jected with the region II-plus MAPs have 50% fewer counts in their livers; 
most of the remaining  counts are found in the blood. 
the results from the experimental and control mice (data not 
shown). 
Discussion 
Here we analyze some of the structural features of region 
II-plus of  the malarial CS required for recognition of the HSPG 
receptors on the hepatocyte membrane. One of our main con- 
clusions is that this interaction is dependent upon the cluster 
of positively charged amino acids and the adjoining hydro- 
phobic residues found at the COOH-terminal of region II- 
plus. Since the hepatocyte receptors are HSPGs, it is likely 
that the positively charged amino acids form ionic bonds with 
the sulfated-glycosaminoglycan  (GAG) chains of the receptor. 
In addition, the protein-carbohydrate  interaction may be sta- 
bilized by interactions between side chains of the adjoining 
hydrophobic amino acids with nonpolar groups of the sac- 
charides (29). 
The present and previous findings (1, 28) also highlight 
the importance of aggregation of CS and of region II-plus 
for binding activity to hepatocytes in vitro and in vivo. The 
experiments depicted in Fig. 4 show that the inhibitory ac- 
tivity of the region II-plus peptides increases with the degree 
of aggregation. Mass spectrometry shows that the early frac- 
tions contain covalently linked tetramers, trimers, and dimers 
as well as noncovalently associated monomers. Although we 
do not know the precise molar proportions of the species 
in the aggregate fractions, if we assume that the average ag- 
gregate size in fraction  16 is tetramers and in fraction 19 is 
trimers (Fig. 4), then 50% inhibition of CS binding is achieved 
with an "~50-nM concentration of the tetramer and an ',~500- 
nM of the trimer.  In other words,  the addition of a single 
monomer to a region II-plus aggregate leads to a 10-fold in- 
crease in binding avidity  for the HSPG receptors.  If this 
reasoning is correct, it would explain the remarkable speed 
and effaciency  of sporozoite infectivity since the parasite sur- 
face coat contains  a very high concentration of the region 
II-plus ligand. 
We also provide evidence that native CS, in extracts of 
P. berghi sporozoites, contains disulfide-linked  aggregates. This 
finding is in apparent contradiction to previous reports (for 
a review see reference 30). Most likely, these aggregates were 
not detected before because they are present at much lower 
concentrations  than the CS monomers. Native CS contains 
two pairs of cysteines,  one within region II-plus and the other 
further downstream, close to the COOH terminus. How- 
ever, the position of the intra- and interchain disulfide bonds 
is not known. Nevertheless, the tightly woven coat created 
by these disulfide-linked aggregates on the parasite surface 
is continuously released by the parasite (31, 32) and can be 
seen as a morphologically distinct  sheath when sporozoites 
are treated with antibodies to the repeat-containing  domain 
of CS (circumsporozoite  reaction).  As suggested elsewhere 
(33), the release of the CS sheath may be a necessary event 
during hepatocyte invasion. The high binding avidity between 
the surface coat of the parasite and the hepatocyte receptors 
would require the parasite to leave its CS coat behind, at- 
tached to the HSPGs, in order to enter the hepatocyte. 
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surface of the parasite and the large number of receptor sites 
in the liver (and perhaps also on HepG2 cells), make it difficult 
to compete for the HSPG receptors with region II-plus pep- 
tides orMAPs. In our clearance studies with CS, we inhibited 
its homing to hepatocytes by 50% in mice pretreated with 
,o10 #M region II-plus MAPs, but only when the animals 
were killed 2 rain after CS injection.  This inhibitory effect 
disappeared if the mice were killed 15 min after CS injection. 
In addition,  sporozoite invasion in vitro could be inhibited 
only 30-50% with synthetic peptides. Better region II-plus 
mimics have to be developed in order to effectively prevent 
the attachment of the Velcro-like  surface structure of the para- 
site to the liver HSPGs. 
Since the region II-plus  motif of CS is found in several 
mammalian and nematode proteins (Fig. 1), the identification 
of amino acid residues that are critical for binding to HSPGs 
may be of relevance outside the malaria field. In addition, 
the requirement for multimerization that we have demon- 
strated for CS may be important for these other molecules, 
as most of these proteins  have multiple copies of the con- 
served motif. Thrombospondin is made of three identical 
polypeptide chains, and each chain has three copies of  region 
II-plus (34). UNC-5 has two copies of the motif per poly- 
peptide chain (8). F-spondin (7) and properdin (5) have six 
copies in  close proximity to each other,  and  in addition, 
properdin is aggregated in serum.  Proteins of the terminal 
complement cascade C6-9 contain two to three copies of the 
motif (35), and these proteins assemble during formation of 
the membrane attack complex.  Although the receptors for 
the motif in the non-CS proteins have yet to be identified, 
properdin,  thrombospondin, and  TRAP bind  to  sulfated 
glycoconjugates (36-38).  Most likely the presence of several 
copies of  the region II-plus motif  increases  the binding avidity 
of these proteins for their receptors, which may include cell 
surface and/or extracellular matrix proteoglycans. 
It seems unlikely that only the cysteines are functionally 
relevant in the stretch  of highly conserved,  mostly hydro- 
phobic  amino acids EWSPCSVTCG at the NH2-terminus 
of region II-plus. Others have shown that the CSVTCG se- 
quence mediates cell adhesion in vitro (14-16), platelet aggre- 
gation in vitro,  and melanoma metastasis in mice (12). In 
addition,  the oxidation  state of the cysteines is not impor- 
tant in these studies since the cysteines can be replaced by 
alanines without a loss of function. 
Perhaps the NH2-terminal portion of region II-plus, con- 
taining mostly hydrophobic amino adds, is recognized during 
sporozoite invasion by a different, yet to be identified, hepa- 
tocyte receptor. Alternatively, the side chains of these amino 
acids may also serve to align the cationic side chains of the 
downstream lysine and arginine residues on the same face  of 
the CS for interaction with the anionic HSPGs. The impor- 
tance ofhydrophobic residues in the formation of structures 
in which the basic residues from different monomers are 
aligned with one another has been demonstrated for other 
heparin-binding proteins whose crystal stuctures have been 
resolved or inferred. For example, bovine platelet factor IV 
is a tetramer of identical dimers, and the lysines involved in 
binding heparin  are found on a-helices of each monomer. 
The a-helix of  one monomer is aligned with that of  another 
monomer when a dimer is formed, and the dimer is stabi- 
lized by a cluster of  hydrophobic residues near the helix (39). 
Thrombin is another heparin-binding molecule whose three- 
dimensional  structure  reveals two  continuous  positively 
charged grooves separated by a central wall that is also made 
up of  basic residues (40). Lipoprotein lipase, which also binds 
to heparin, is thought to be active only as a dimer, and the 
segments involved  in dimer formation appear to form a pocket 
flanked by basic residues that is capable of accommodating 
the heparin GAG chain (41). It is not known if the aggregated 
CS molecules on the parasite surface also contain binding 
pockets with defined three-dimensional structures for binding 
specific sulfated oligosaccharides  from hepatocyte HSPGs. Ad- 
ditional work aimed at defining the structure of  the CS ligand 
and the hepatocyte GAG chain receptors should facilitate the 
generation of more potent inhibitors of sporozoite invasion. 
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